Connection

MARY ESTES to Antibodies, Viral

This is a "connection" page, showing publications MARY ESTES has written about Antibodies, Viral.
Connection Strength

4.756
  1. Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
    View in: PubMed
    Score: 0.596
  2. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
    View in: PubMed
    Score: 0.572
  3. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
    View in: PubMed
    Score: 0.427
  4. Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies. Clin Vaccine Immunol. 2015 Feb; 22(2):168-77.
    View in: PubMed
    Score: 0.297
  5. A time-resolved immunoassay to measure serum antibodies to the rotavirus VP6 capsid protein. J Virol Methods. 2013 Apr; 189(1):228-31.
    View in: PubMed
    Score: 0.258
  6. Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol. 2012 Dec; 19(12):1980-3.
    View in: PubMed
    Score: 0.256
  7. High efficiency cross-reactive monoclonal antibody production by oral immunization with recombinant norwalk virus-like particles. Microbiol Immunol. 2006; 50(11):883-8.
    View in: PubMed
    Score: 0.160
  8. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol. 2003 Sep; 108(3):241-7.
    View in: PubMed
    Score: 0.136
  9. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol. 2001 Oct; 75(20):9713-22.
    View in: PubMed
    Score: 0.119
  10. Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses. Nat Commun. 2021 07 14; 12(1):4320.
    View in: PubMed
    Score: 0.118
  11. Human noroviruses: recent advances in a 50-year history. Curr Opin Infect Dis. 2018 10; 31(5):422-432.
    View in: PubMed
    Score: 0.097
  12. Human Monoclonal Antibodies That Neutralize Pandemic GII.4?Noroviruses. Gastroenterology. 2018 12; 155(6):1898-1907.
    View in: PubMed
    Score: 0.096
  13. Identification and Characterization of Single-Chain Antibodies that Specifically Bind GI Noroviruses. PLoS One. 2017; 12(1):e0170162.
    View in: PubMed
    Score: 0.086
  14. Rotavirus Serum IgA Immune Response in Children Receiving Rotarix Coadministered With bOPV or IPV. Pediatr Infect Dis J. 2016 10; 35(10):1137-9.
    View in: PubMed
    Score: 0.084
  15. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996 Sep; 174 Suppl 1:S88-92.
    View in: PubMed
    Score: 0.084
  16. Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection. Clin Vaccine Immunol. 2016 02; 23(2):181-3.
    View in: PubMed
    Score: 0.080
  17. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
    View in: PubMed
    Score: 0.077
  18. Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis. 2015 Aug 01; 212(3):397-405.
    View in: PubMed
    Score: 0.075
  19. Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol. 2015 Feb; 22(2):221-8.
    View in: PubMed
    Score: 0.075
  20. Characterization of cross-reactive norovirus-specific monoclonal antibodies. Clin Vaccine Immunol. 2015 Feb; 22(2):160-7.
    View in: PubMed
    Score: 0.074
  21. Assessment of epitope-blocking assays for measuring antibody to rotavirus. J Virol Methods. 1994 Jul; 48(2-3):293-300.
    View in: PubMed
    Score: 0.072
  22. Identification of human single-chain antibodies with broad reactivity for noroviruses. Protein Eng Des Sel. 2014 Oct; 27(10):339-49.
    View in: PubMed
    Score: 0.072
  23. Exposure to human and bovine noroviruses in a birth cohort in southern India from 2002 to 2006. J Clin Microbiol. 2013 Jul; 51(7):2391-5.
    View in: PubMed
    Score: 0.066
  24. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis. 1993 Mar; 167(3):577-83.
    View in: PubMed
    Score: 0.066
  25. Characterization of serum antibody responses to natural rotavirus infections in children by VP7-specific epitope-blocking assays. J Clin Microbiol. 1992 May; 30(5):1056-61.
    View in: PubMed
    Score: 0.062
  26. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol. 2012 Feb; 19(2):284-7.
    View in: PubMed
    Score: 0.061
  27. Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol. 2011 Jul; 18(7):1187-90.
    View in: PubMed
    Score: 0.058
  28. Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J Infect Dis. 2006 Nov 15; 194(10):1422-7.
    View in: PubMed
    Score: 0.042
  29. Evaluation of serum antibody responses against the rotavirus nonstructural protein NSP4 in children after rhesus rotavirus tetravalent vaccination or natural infection. Clin Diagn Lab Immunol. 2005 Oct; 12(10):1157-63.
    View in: PubMed
    Score: 0.039
  30. Diagnosis of norwalk virus infection by indirect enzyme immunoassay detection of salivary antibodies to recombinant norwalk virus antigen. Clin Diagn Lab Immunol. 2004 Nov; 11(6):1028-34.
    View in: PubMed
    Score: 0.037
  31. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine. 2003 Sep 08; 21(25-26):3885-900.
    View in: PubMed
    Score: 0.034
  32. Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J Clin Microbiol. 2002 Jul; 40(7):2459-65.
    View in: PubMed
    Score: 0.031
  33. High-Resolution Mapping of Human Norovirus Antigens via Genomic Phage Display Library Selections and Deep Sequencing. J Virol. 2020 12 09; 95(1).
    View in: PubMed
    Score: 0.028
  34. Identification of an epitope common to genogroup 1 "norwalk-like viruses". J Clin Microbiol. 2000 Apr; 38(4):1656-60.
    View in: PubMed
    Score: 0.027
  35. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol. 1999 Jun; 73(6):4813-22.
    View in: PubMed
    Score: 0.025
  36. Expression and self-assembly of Grimsby virus: antigenic distinction from Norwalk and Mexico viruses. Clin Diagn Lab Immunol. 1999 Jan; 6(1):142-5.
    View in: PubMed
    Score: 0.025
  37. Determination of the duration of a primary immune response and the ID50 of ALA rabbit rotavirus in rabbits. Arch Virol. 1997; 142(11):2281-94.
    View in: PubMed
    Score: 0.021
  38. Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies. Virology. 1996 Mar 01; 217(1):252-61.
    View in: PubMed
    Score: 0.020
  39. Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis. 1994 Jul; 170(1):34-43.
    View in: PubMed
    Score: 0.018
  40. Localization of rotavirus VP4 neutralization epitopes involved in antibody-induced conformational changes of virus structure. J Virol. 1994 Jun; 68(6):3955-64.
    View in: PubMed
    Score: 0.018
  41. A subviral particle binding domain on the rotavirus nonstructural glycoprotein NS28. Virology. 1993 Jun; 194(2):665-73.
    View in: PubMed
    Score: 0.017
  42. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
    View in: PubMed
    Score: 0.015
  43. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med. 2011 Jul 28; 365(4):337-46.
    View in: PubMed
    Score: 0.015
  44. Serologic and mucosal immune response to rotavirus infection in the rabbit model. J Virol. 1991 May; 65(5):2562-71.
    View in: PubMed
    Score: 0.014
  45. Localization of VP4 neutralization sites in rotavirus by three-dimensional cryo-electron microscopy. Nature. 1990 Feb 01; 343(6257):476-9.
    View in: PubMed
    Score: 0.013
  46. Molecular biology and immunology of rotavirus infections. Immunol Invest. 1989 Jan-May; 18(1-4):571-81.
    View in: PubMed
    Score: 0.012
  47. Detection of human calicivirus antigen and antibody by enzyme-linked immunosorbent assays. J Clin Microbiol. 1988 Oct; 26(10):2001-5.
    View in: PubMed
    Score: 0.012
  48. Differential requirements for T cells in viruslike particle- and rotavirus-induced protective immunity. J Virol. 2008 Mar; 82(6):3135-8.
    View in: PubMed
    Score: 0.012
  49. Ricin toxin B subunit enhancement of rotavirus NSP4 immunogenicity in mice. Viral Immunol. 2006; 19(1):54-63.
    View in: PubMed
    Score: 0.010
  50. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine. 2006 Feb 20; 24(8):1170-9.
    View in: PubMed
    Score: 0.010
  51. The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. J Virol. 2004 Jul; 78(13):6974-81.
    View in: PubMed
    Score: 0.009
  52. Simian rhesus rotavirus is a unique heterologous (non-lapine) rotavirus strain capable of productive replication and horizontal transmission in rabbits. J Gen Virol. 2000 May; 81(Pt 5):1237-49.
    View in: PubMed
    Score: 0.007
  53. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol. 1998 Nov; 72(11):9233-46.
    View in: PubMed
    Score: 0.006
  54. Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol. 1997 Nov; 71(11):8707-17.
    View in: PubMed
    Score: 0.006
  55. Recombinant Norwalk virus-like particles as an oral vaccine. Arch Virol Suppl. 1996; 12:243-9.
    View in: PubMed
    Score: 0.005
  56. Rabbit model of rotavirus infection. J Virol. 1988 May; 62(5):1625-33.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.